Mirvetuximab Soravtansine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mirvetuximab Soravtansine
Accession Number
DB12489
Type
Biotech
Groups
Investigational
Description

Mirvetuximab Soravtansine has been used in trials studying the treatment of Ovarian cancer, Endometrial Cancer, Fallopian tube cancer, Epithelial Ovarian Cancer, and Primary Peritoneal Cancer, among others.

Synonyms
  • IMGN853
Categories
UNII
98DE7VN88D
CAS number
1453084-37-1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe serum concentration of (R)-warfarin can be increased when it is combined with Mirvetuximab Soravtansine.
(S)-WarfarinThe serum concentration of (S)-Warfarin can be increased when it is combined with Mirvetuximab Soravtansine.
3-isobutyl-1-methyl-7H-xanthineThe metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Mirvetuximab Soravtansine.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Mirvetuximab Soravtansine.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Mirvetuximab Soravtansine.
7-DeazaguanineThe metabolism of 7-Deazaguanine can be decreased when combined with Mirvetuximab Soravtansine.
7,9-DimethylguanineThe metabolism of 7,9-Dimethylguanine can be decreased when combined with Mirvetuximab Soravtansine.
8-azaguanineThe metabolism of 8-azaguanine can be decreased when combined with Mirvetuximab Soravtansine.
8-chlorotheophyllineThe metabolism of 8-chlorotheophylline can be decreased when combined with Mirvetuximab Soravtansine.
9-aminocamptothecinThe metabolism of 9-aminocamptothecin can be decreased when combined with Mirvetuximab Soravtansine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
131704323
PubChem Substance
347828725
ChemSpider
64873336

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentFOLR-1 Positive Solid Tumors1
1RecruitingTreatmentBRCA1 Gene Mutation / Brca2 Gene Mutation / Folate Receptor Alpha Positive / Platinum Resistant Ovarian Cancer / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Recurrent Uterine Carcinosarcoma / Recurrent Uterine Corpus Carcinoma / Recurrent Uterine Serous Carcinoma1
1RecruitingTreatmentRecurrent Breast Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Recurrent Uterine Corpus Carcinoma / Triple-Negative Breast Carcinoma1
1WithdrawnTreatmentBreast Cancer Triple Negative1
1, 2Active Not RecruitingTreatmentEndometrial Cancer / Fallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Cancer1
2CompletedTreatmentAnatomic Stage II Breast Cancer AJCC v8 / Anatomic Stage IIA Breast Cancer AJCC v8 / Anatomic Stage IIB Breast Cancer AJCC v8 / Anatomic Stage III Breast Cancer AJCC v8 / Anatomic Stage IIIA Breast Cancer AJCC v8 / Anatomic Stage IIIB Breast Cancer AJCC v8 / Anatomic Stage IIIC Breast Cancer AJCC v8 / Anatomic Stage IV Breast Cancer AJCC v8 / Estrogen Receptor Negative / Folate Receptor Alpha Positive / HER2/Neu Negative / Malignant Neoplasm of Breast / Progesterone Receptor Negative / Prognostic Stage II Breast Cancer AJCC v8 / Prognostic Stage IIA Breast Cancer AJCC v8 / Prognostic Stage IIB Breast Cancer AJCC v8 / Prognostic Stage III Breast Cancer AJCC v8 / Prognostic Stage IIIA Breast Cancer AJCC v8 / Prognostic Stage IIIB Breast Cancer AJCC v8 / Prognostic Stage IIIC Breast Cancer AJCC v8 / Prognostic Stage IV Breast Cancer AJCC v8 / Triple-Negative Breast Carcinoma1
2Not Yet RecruitingTreatmentRecurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma1
2RecruitingTreatmentEndometrial Cancer2
2WithdrawnTreatmentEndometrial Adenocarcinomas / Endometrial Cancer / Endometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma1
3CompletedTreatmentFallopian Tube Cancer / Ovarian Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Carcinoma1
3RecruitingTreatmentFallopian Tube Cancer / Malignant Peritoneal Neoplasm / Ovarian Epithelial Cancer2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [PubMed:11020135]

Drug created on October 20, 2016 16:35 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates